logo

For the Inventor, By the Inventor

Towson, MD, United States of America

Harry C Dietz

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 99(Granted Patents)


Company Filing History:

goldMedal13 out of 3,687 
 
Johns Hopkins University
 patents

Years Active: 1998-2024

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 11938135 - Compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders (2024-03-26),
2. 11771703 - Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression (2023-10-03),
3. 11692028 - Map kinase pathway targets for the treatment of Marfan syndrome (2023-07-04),
4. 11357748 - Methods for treating mendelian disorders of the epigenetic machinery (2022-06-14),
5. 11273148 - Targeted epigenetic therapy for inherited aortic aneurysm condition (2022-03-15),
6. 11219670 - Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies (2022-01-11),
7. 10568854 - Compositions and methods for treating kabuki syndrome and related disorders (2020-02-25),
8. 10246498 - Genetically encoded histone reporter allele constructs (2019-04-02),
9. 8597646 - Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders (2013-12-03),
10. 6924096 - Delivery construct for antisense nucleic acids and methods of use (2005-08-02),
11. 6048965 - Mammalian regulator of nonsense-mediated RNA decay (2000-04-11),
12. 5994119 - Mammalian regulator of nonsense-mediated RNA decay (1999-11-30),
13. 5814500 - Delivery construct for antisense nucleic acids and methods of use (1998-09-29),

Title: The Innovations of Harry C. Dietz

Introduction

Harry C. Dietz is a prominent inventor based in Towson, MD (US), known for his significant contributions to the field of medical research and treatment. With a total of 13 patents, Dietz has made remarkable strides in addressing complex health issues, particularly those related to connective tissue disorders.

Latest Patents

Among his latest patents, Dietz has developed compositions and methods for treating vascular Ehlers Danlos syndrome and associated disorders. This invention focuses on innovative approaches to manage and treat this challenging condition. Another notable patent is his targeted epigenetic therapy against the distal regulatory element of TGFβ2 expression. This patent provides methods and compositions for diagnosing, treating, and preventing TGFβ2-associated diseases, including Scleroderma, fibrotic diseases, grade 4 glioblastoma (GBM), and Primary Open-Angle Glaucoma (POAG). These advancements highlight Dietz's commitment to improving patient outcomes through innovative medical solutions.

Career Highlights

Harry C. Dietz is affiliated with The Johns Hopkins University, where he continues to engage in groundbreaking research. His work has not only contributed to the scientific community but has also paved the way for new therapeutic strategies in treating complex diseases.

Collaborations

Dietz has collaborated with esteemed colleagues, including Hans Tomas Bjornsson and Joel Benjamin. These partnerships have further enhanced the impact of his research and innovations in the medical field.

Conclusion

Harry C. Dietz exemplifies the spirit of innovation in medical research, with a focus on developing effective treatments for serious health conditions. His contributions through patents and collaborations continue to shape the future of medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…